Price
$228.30-2.34%Social Signal Score
Analyst Ratings
33 analysts52-week range
- Last close
- $228.30
- Off 52w high
- -8.2%
- 200-day average
- $218.03
- vs 200-day
- +4.7%
Revenue
$63.86B+99.31%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason Hollar
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Employees
- 61,344
- Beta
- 0.52
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 5.06
Financials
Revenue
$63.86B+99.3%Net Income
$394.00M+27.5%EBITDA
$1.12B+57.4%Free Cash Flow
$1.43B+35600.0%EPS (diluted)
$1.69+76.0%Shares Outstanding (diluted)
237.00M-26.4%Operating Expenses
$1.63BCash & Debt
$4.86BReturn of Capital
$470.00MRevenue by Segment (annual)
$254.34BDividend per Share
$0.52Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $254.25B | $1.71B | $7.27 |
| 2025 | $222.58B | $1.56B | $6.48 |
| 2024 | $226.83B | $852.00M | $3.48 |
| 2023 | $204.98B | $330.00M | $1.26 |
| 2022 | $181.33B | $-938.00M | $-3.34 |
| 2021 | $162.47B | $611.00M | $2.09 |
| 2020 | $152.92B | $-3.69B | $-12.60 |
| 2019 | $145.53B | $1.36B | $4.54 |
| 2018 | $136.81B | $256.00M | $0.82 |
| 2017 | $129.98B | $1.29B | $4.06 |
| 2016 | $121.55B | $1.43B | $4.36 |
| 2015 | $102.53B | $1.22B | $3.66 |
| 2014 | $91.08B | $1.17B | $3.42 |
| 2013 | $101.09B | $334.00M | $0.98 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CAH's reported EPS growth of 16.7% a year over 13 years.
- EPS in 5 years
- $15.72
- Implied price
- $518.76
- Return from $228.30
- 17.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $257.92 — today's price is already 11.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 23 | 28 | 33 | 38 | 43 |
|---|---|---|---|---|---|
| 6.7% | 0.2% | 4.3% | 7.7% | 10.8% | 13.6% |
| 11.7% | 4.9% | 9.1% | 12.8% | 16.0% | 18.9% |
| 16.7% | 9.6% | 14.0% | 17.8% | 21.2% | 24.2% |
| 21.7% | 14.3% | 18.9% | 22.9% | 26.4% | 29.6% |
| 26.7% | 19.0% | 23.8% | 27.9% | 31.6% | 34.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80+60.00%Social Signal Score
Mentions (70)
- Newszacks.com·15h ago·Positive
Cardinal Health (CAH) Outperforms Broader Market: What You Need to Know Cardinal Health (CAH) closed the most recent trading day at $233.12, moving +2.11% from the previous trading session.
View source ↗ - News (RSS)investing·4d ago·Neutral
Cardinal Health rises on extended CVS distribution deal
View source ↗ - Newsprnewswire.com·5d ago·Neutral
…ters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health through June 30, 2032, reflecting the continuation of Cardinal Health's current scope of distribution services. "We value our long-standing partnership with CVS Health and look forward to continuing …
View source ↗ - Newsprnewswire.com·5d ago·Neutral
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5 DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2027 on November 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Cardinal Health: I'm Still Buying After Checking The Numbers Cardinal Health remains a Buy, driven by robust FY2026 results, strong cash flow, and credible FY2027 guidance. CAH delivered 14% revenue growth, 20% gross margin expansion, and doubled free cash flow, despite ongoing thin margins and higher current liabilities. FY2027 guidance targets 13-15% non-GAAP EPS growth, with profit improvement expected from both Pharmaceutical and Specialty Solutions and higher-margin 'Other' segments.
View source ↗ - Newszacks.com·7d ago·Neutral
At-Home Healthcare Is Growing Fast: Can CAH Ride the Trend? At-Home Solutions is powering CAH???s growth strategy as investments, acquisitions and technology help it scale in home-based healthcare.
View source ↗ - Newszacks.com·10d ago·Neutral
Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You Trade Cardinal Health (CAH) closed at $220.22 in the latest trading session, marking a -1.08% move from the prior day.
View source ↗ - News (RSS)investing·11d ago·Negative
Cardinal Infrastructure expands credit facility to $550 million
View source ↗ - Newszacks.com·12d ago·Positive
Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·13d ago·Neutral
CVS vs. CAH: Which Healthcare Services Stock Is the Better Pick Now? CVS Health and Cardinal Health are benefiting from healthcare growth, but differences in performance, valuation and targets shape the outlook.
View source ↗ - Newszacks.com·13d ago·Neutral
Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery? CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.
View source ↗ - Newszacks.com·13d ago·Neutral
Cardinal (CAH) Is Considered a Good Investment by Brokers: Is That True? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds Cardinal Health NYSE: CAH CEO Jason Hollar said the company expects fiscal 2027 to extend the broad operating momentum it generated in fiscal 2026, with all five operating segments positioned for what he described as a “constructive” period.
View source ↗ - News (RSS)yahoo·16d ago·Neutral
Cardinal Health Sees Growth Normalize as Specialty, At-Home Investments Expand
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Cardinal Health Sees Growth Normalize as Specialty, At-Home Investments Expand Cardinal Health NYSE: CAH CEO Jason Hollar said the company's fiscal 2026 performance was supported by double-digit earnings growth across each of its five operating segments, while fiscal 2027 guidance reflects continued growth from a more normalized base.
View source ↗ - News (RSS)yahoo·17d ago·Neutral
Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better
View source ↗ - Newszacks.com·19d ago·Neutral
Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure? Cardinal Health expects IRA pricing changes to pressure Pharma revenues while protecting profitability through compensation and durable distribution agreements.
View source ↗ - News (Alpha Vantage)Simply Wall Street·20d ago·Neutral
Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)? McKesson (MCK) recently increased its full-year EPS guidance, expecting 13-15% growth, and announced plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO in late 2027. The company is also acquiring Precision Medicine Group to enhance its oncology and biopharma services. While these developments signal operational strength and strategic expansion, the core investment narrative, including risks like dru
View source ↗ - Newszacks.com·20d ago·Neutral
Cardinal Health (CAH) Registers a Bigger Fall Than the Market: Important Facts to Note The latest trading day saw Cardinal Health (CAH) settling at $232.36, representing a -1.08% change from its previous close.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Cardinal Health, Inc. (CAH) Presents at 2026 Global Healthcare Conference Transcript Cardinal Health, Inc. (CAH) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·20d ago·Neutral
Cardinal Energy declares CAD 0.06 dividend
View source ↗ - News (RSS)seekingalpha·21d ago·Positive
Cardinal Health, Inc. (CAH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Cardinal Health, Inc. (CAH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Cardinal Health, Inc. (CAH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·24d ago·Positive
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue? Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
View source ↗ - Newszacks.com·25d ago·Neutral
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue? Cardinal (CAH) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·27d ago·Neutral
Cardinal Health (CAH) Declines More Than Market: Some Information for Investors In the latest trading session, Cardinal Health (CAH) closed at $240.49, marking a -2.71% move from the previous day.
View source ↗ - Newszacks.com·27d ago·Neutral
Is Cardinal Health Building a New Tech-Enabled Healthcare Platform? Technology is becoming a bigger part of CAH's strategy, linking distribution, specialty services and logistics through digital workflows.
View source ↗ - News (RSS)yahoo·32d ago·Neutral
Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”
View source ↗ - Newszacks.com·32d ago·Positive
Cardinal Health (CAH) is a Top-Ranked Growth Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·33d ago·Negative
Is Generics Still a Quiet Profit Engine for Cardinal Health? Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
View source ↗ - Newszacks.com·35d ago·Positive
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
View source ↗ - Newszacks.com·38d ago·Positive
Cardinal Health (CAH) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·42d ago·Positive
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now CAH enters fiscal 2027 with strong specialty growth, but IRA pricing changes, GMPD challenges and heavy CapEx pose risks.
View source ↗ - News (RSS)fool·43d ago·Positive
Cardinal Health's CFO Moved $9.9 Million of Stock. Here's What Long-Term Investors Should Know Alt divested part of his direct equity stake after the stock surged 57% over the past year, retaining 20,495 shares worth $4.82 million.
View source ↗ - News (RSS)fool·43d ago·Positive
Cardinal Health's Medical Segment Boss Sold $8 Million in Stock. Here's What to Know This insider sale cut an equity stake following a strong 57% one-year stock run, leaving $4.2 million in direct holdings.
View source ↗ - Newsfool.com·44d ago·Neutral
What to Know About the Latest Sale From Cardinal Health's Chief Accounting Officer The sale involved 2,302 shares at $237.39 per share, resulting in a transaction value of $546,500. All shares were held directly; no indirect ownership through entities or trusts was disclosed in the filing.
View source ↗ - Newsfool.com·44d ago·Positive
Cardinal Health's CFO Moved $9.9 Million of Stock. Here's What Long-Term Investors Should Know The transaction involved 42,000 shares with a total value of ~$9.9 million on August 18. Following the sale, the executive retains 20,495 shares held directly, with no reported indirect ownership.
View source ↗ - Newsfool.com·44d ago·Neutral
Cardinal Health's Pharma Chief Sold 7,354 Shares and Still Grew Her Stake by 47%. Here's How That Happened Deborah Weitzman sold 7,354 shares for approximately $1.7 million on August 18. The entire disposition was executed through direct ownership, with no indirect holdings reported in the filing.
View source ↗ - Newsfool.com·44d ago·Negative
Cardinal Health's Legal Chief Just Filed an Insider Transaction. Here's What to Know The sale realized $7.0 million based on a weighted average execution price. The transaction represents a 47% reduction in Mayer direct equity holdings.
View source ↗ - Newsfool.com·44d ago·Positive
Cardinal Health's CEO Moved 124,529 Shares in Two Days. Here's What Long-Term Investors Should Know Jason M. Hollar disposed of 125,000 shares at a weighted average price of $235.89 per share across two trading sessions. The divestment involved only directly held shares; Hollar retains nearly 191,000 shares valued at $44.76 million following the sale.
View source ↗ - Newszacks.com·46d ago·Positive
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)yahoo·47d ago·Positive
Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story
View source ↗ - News (RSS)seekingalpha·47d ago·Positive
Cardinal Health: Precision Medicine Drives A Sustained Revenue Growth Path
View source ↗ - Newsseekingalpha.com·48d ago·Positive
… its Pharmaceutical and Specialty Solutions segment and precision medicine exposure. PSS revenues reached $234.8 billion in FY2026, up 15% YoY, accounting for 92% of CAH's total revenues, with further growth expected from gene therapy and Solaris Health. Precision medicine, growing at a projected 17% CAGR, positions the company to capture a substantial share of an underserved market, supporting long-term top-line expansion.
View source ↗ - News (RSS)yahoo·48d ago·Positive
Cardinal (CDNL) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·48d ago·Positive
Here's Why Cardinal Health (CAH) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·49d ago·Positive
3 Reasons Growth Investors Will Love Cardinal (CAH) Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·53d ago·Positive
Cardinal Health Stock Hits a Record High After Earnings: Is CAH Still a Buy? Cardinal Health (CAH) gave investors plenty to like in its fiscal fourth-quarter report this week, sending shares to a record high of $258 as Wall Street digests another earnings beat and an encouraging FY27 outlook.
View source ↗ - Newszacks.com·54d ago·Positive
CAH Q4 Earnings Call Centers on Fiscal 2027 Growth Outlook Cardinal Health targets 13%-15% fiscal 2027 EPS growth as pharma demand normalizes and specialty, At-Home and buybacks remain key priorities for execution.
View source ↗ - News (Finnhub)CNBC·55d ago·Positive
We're lifting our price target on Cardinal Health after issuing rosy profit guidance The quarter wasn't totally clean, but strong profitability matters the most.
View source ↗ - News (RSS)seekingalpha·55d ago·Positive
Cardinal Health rises on strong fiscal 2027 EPS outlook, FQ4 bottom line beat
View source ↗ - Newszacks.com·55d ago·Neutral
CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Cardinal Health Q4 Earnings Call Highlights Cardinal Health NYSE: CAH reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment.
View source ↗ - News (Marketaux)rttnews.com·55d ago·Positive
Cardinal Health Q4 Profit Climbs, Sees Growth In FY27; Approves $5 Bln Buyback Healthcare services company Cardinal[+199 characters]
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Cardinal Health, Inc. (CAH) Q4 2026 Earnings Call Transcript Cardinal Health, Inc. (CAH) Q4 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·55d ago·Negative
Existing Home Sales Data in Focus Pre-market futures are correcting Monday's slight selloff at this hour; ultimately, as we had said in this space yesterday, we don't expect much movement either direction until inflation reports begin to hit the tape Wednesday morning with the Consumer Price Index (CPI) Inflation Rate. The Dow is +71 points presently, the S&P 500 +16 and the Nasdaq +129 points.
View source ↗ - Newszacks.com·55d ago·Neutral
Small Biz Index, Existing Home Sales & More Earnings We don't expect much movement either direction until inflation reports begin to hit the tape Wednesday morning.
View source ↗ - News (RSS)investing.com·55d ago·Neutral
Why is Cardinal Health stock surging today?
View source ↗ - News (RSS)seekingalpha·55d ago·Neutral
Cardinal Health Non-GAAP EPS of $2.91 beats by $0.49, revenue of $63.67B misses by $1.44B
View source ↗ - News (RSS)seekingalpha·55d ago·Neutral
Cardinal Health declares $0.5158 dividend
View source ↗ - Newszacks.com·55d ago·Negative
Compared to Estimates, Cardinal (CAH) Q4 Earnings: A Look at Key Metrics Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·56d ago·Positive
Cardinal Health (CAH) Q4 Earnings Beat Estimates Cardinal Health (CAH) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.42 per share. This compares to earnings of $2.08 per share a year ago.
View source ↗ - Newsreuters.com·56d ago·Negative
Cardinal Health forecasts full-year profit above estimates on specialty drug strength U.S. drug distributor Cardinal Health on Tuesday forecast fiscal 2027 profit well above Wall Street expectations after topping fourth-quarter profit estimates, driven by sustained demand for specialty drugs.
View source ↗ - Newsbarrons.com·56d ago·Positive
Can Cardinal Health's Strong Earnings Guidance Offset a Mixed Quarter? Cardinal Health reports mixed quarterly performance across its business segments as earnings get a lift from one-time tariff refunds.
View source ↗ - Newswsj.com·56d ago·Neutral
Cardinal Health Logs Mixed Sales, Sees Growth in New Year Cardinal Health had a mixed fiscal fourth quarter in terms of sales across its two main business lines, but expects revenue to rise in both segments in the new fiscal year.
View source ↗ - Newsprnewswire.com·56d ago·Positive
Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance Fourth quarter revenue increased 6% to $63.7 billion Fourth quarter GAAP 1 diluted EPS increased 70% to $1.70 Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91 For fiscal year 2026, excluding the IEEPA tariff refun
View source ↗ - Newsprnewswire.com·56d ago·Neutral
Cardinal Health Board of Directors Approves Quarterly Dividend DUBLIN, Ohio,, Aug. 11, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2026 to shareholders of record at the close of business on October 1, 2026.
View source ↗ - Newsbenzinga.com·56d ago·Neutral
Cardinal Health Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Cardinal Health, Inc. (NYSE:CAH) will release its fourth quarter earnings report before the opening bell on Tuesday, Aug. 11.
View source ↗ - News (RSS)seekingalpha·56d ago·Neutral
Cardinal Health Q4 2026 Earnings Preview
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $2.95 per share
Typical surprise +12.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$2.91 vs $2.42beat
- Thu, Apr 30$3.17 vs $2.79beat
- Thu, Feb 5$2.63 vs $2.34beat
- Thu, Oct 30$2.55 vs $2.18beat
- Tue, Aug 12$2.08 vs $2.04beat
- Thu, May 1$2.35 vs $2.17beat
Estimates and results for CAH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CAH officers and directors.
- Bought
- —
- Sold
- $80.4m
0 trades
45 trades
- Scherer Mary C.sold
- Scherer Mary C.sold
- Hollar Jason M.sold
- Hollar Jason M.sold
- Hollar Jason M.sold
- Hollar Jason M.sold
- Hollar Jason M.sold
- Hollar Jason M.sold
55 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Oct 29, 2025 (5d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Sell$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed May 20, 2025 (6d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed May 7, 2025 (2d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Mar 20, 2025 (3d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Jan 28, 2025 (7d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Sep 23, 2024 (3d later)Buy$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 6, 2024 (2d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 2, 2024 (123d later)Buy$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 2, 2024 (91d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Sell$1,001 - $15,000
- Jonathan Jacksonhouse · IL01 · disclosed Feb 15, 2024 (34d later)Buy$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 6, 2023 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 7, 2023 (27d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.